Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27881964 | 0.89 | FLT1 (0.44) | SOS1PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL6893360 | 0.84 | KMT2A (0.41) | SOS1PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL13160673 | 0.83 | SOS1 (0.47) | SOS1PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL4618133 | 0.83 | SOS1 (0.54) | SOS1PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL1940923 | 0.83 | PTGS2 (0.42) | SOS1PTGS2PTGS1CA2 | |
| SCHEMBL6887529 | 0.82 | CA1 (0.48) | MEN1KMT2ACA2HTT | |
| SCHEMBL68413 | 0.82 | KMT2A (0.48) | SOS1PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL1700007 | 0.81 | SOS1 (0.67) | SOS1PTGS2PTGS1CA2 | |
| SCHEMBL6763102 | 0.81 | MEN1 (0.54) | SOS1PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL6741781 | 0.81 | AGTR1 (0.49) | SOS1PTGS2PTGS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 538 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109608369-B | Sulfonyl ester group anthraquinone derivative and preparation method and application thereof | 广西大学 | 2021-04-09 | — | — | CN | claimed |
| US-20080038867-A1 | METHOD FOR MANUFACTURING A THIN FILM TRANSISTOR ARRAY PANEL | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2008-02-14 | — | — | US | claimed |
| EP-1377589-B1 | OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2005-09-07 | — | — | EP | claimed |
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | disclosed |
| US-20250250265-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | VANDERBILT UNIVERSITY | 2025-08-07 | — | — | US | disclosed |
| EP-4596534-A1 | NONCOVALENT SMALL-MOLECULE INHIBITORS OF THE KEAP1-NRF2 INTERACTION | University of Copenhagen (DK) | 2025-08-06 | — | — | EP | disclosed |
| CN-119143691-B | Thiadiazole derivative and preparation method and application thereof | 山东大学日照研究院 | 2025-06-24 | — | — | CN | disclosed |
| EP-4570798-A1 | AROMATIC HETEROCYCLIC CYCLOHEXYL AMINOALKYL PIPERIDINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Jiangsu NHWA Pharmaceutical Co., Ltd (CN) | 2025-06-18 | — | — | EP | disclosed |
| CN-119677734-A | Aromatic heterocyclic cyclohexane amino alkyl piperidine derivative, preparation method and application thereof | 江苏恩华药业股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119462588-A | Flavone derivative containing sulfonamide structure and preparation method and application thereof | 上海中医药大学附属曙光医院 | 2025-02-18 | — | — | CN | disclosed |
| CN-119390708-A | Novel curcumenol derivative and synthetic method and application thereof | 天津中医药大学 | 2025-02-07 | — | — | CN | disclosed |
| US-6245763-B1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1086097-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER INC. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
| EP-1056743-A1 | BENZAMINE DERIVATIVES | MERCK PATENT GmbH (DE) | 2000-12-06 | — | — | EP | disclosed |
| US-6037356-A | ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1999064415-A1 | SULFONYLBENZENE COMPOUNDS AS ANTI-INFLAMMATORY/ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999031092-A1 | BENZAMINE DERIVATIVES | MERCK PATENT GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| US-4600709-A | ANTIEDEMIC, HYPOTENSIVE, DIURETIC | CIBA-GEIGY AG (CH) | 1986-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | SOS1 2617/4885PTGS2 1092/4885PTGS1 1015/4885 |
| US-20250250265-A1 | BENZOTHIAZOLE-PHENYLSULFONYL-PIPERIDINE ANALOGS AS ACTIVATORS OF NACYLPHOSPHATIDYLETHANOLAMINE HYDROLYZING PHOSPHOLIPASE D | PLD1, PLD2, NAPEPLD | SOS1 4389/4885PTGS2 1334/4885PTGS1 1126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.